Lab data show an experimental treatment increased immune cells in liver tumors.

Oncolytics Biotech® Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer That Make Tumors Susceptible to Immunotherapy

SAN DIEGO, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced data published in the Proceedings of the National Academy of Sciences show pelareorep’s ability to…

Lab data show an experimental treatment increased immune cells in liver tumors.

The Sept. 28 paper reports increased CD8+ T-cell density in preclinical data; Oncolytics says liver cancer is not an indication it plans to pursue now.